BRITISH AMERICAN TOBACCO (BATS.L)

Key Updates

British American Tobacco advanced +2.10% to £4,566 since the June 8 report, continuing the recovery trajectory from early June lows and extending YTD gains to +8.35%. The modest uptick occurred against a backdrop of intensifying competitive dynamics in the reduced-risk product (RRP) space, with Philip Morris International's IQOS brand achieving landmark recognition as the #74 most valuable global brand according to Kantar's BrandZ 2026 ranking. This development underscores the accelerating consumer migration toward heat-not-burn alternatives, where BAT faces formidable competition despite its own smoke-free pivot. The investment thesis remains under pressure as PMI's IQOS platform demonstrates superior brand equity with 35 million users and $10 billion in annual revenues, highlighting execution gaps in BAT's new-category strategy.

Current Trend

BAT shares have established a constructive pattern following the early June correction, with the stock recovering +5.32% from the £4,335 low reached on June 4. The YTD performance of +8.35% positions the shares materially above 2026 opening levels, though the recent volatility reflects ongoing investor recalibration of growth expectations. The 6-month gain of +6.11% demonstrates sustained momentum despite the June 2 guidance revision that triggered a -3.71% single-session decline. Near-term price action suggests stabilization around the £4,450-£4,550 range, with the stock digesting the transition from eight-year highs achieved in late May. The 1-month gain of +4.27% indicates renewed buyer interest following the selloff, though volume patterns suggest cautious positioning ahead of further clarity on new-category execution.

Investment Thesis

The core investment thesis centers on BAT's ability to execute a profitable transition from combustible cigarettes to reduced-risk products while maintaining cash generation from the legacy business. Management projects mid-teens revenue growth in new categories (upgraded from low double-digits) against a backdrop of accelerating cigarette volume declines now estimated at -2.5% versus the prior -2.0% forecast, as disclosed in the June 2 guidance revision. The thesis assumes BAT can capture meaningful share in vapes and nicotine pouches while defending pricing power in combustibles across key markets. Critical to this narrative is whether new-category margins can offset volume-driven compression in traditional products, particularly given competitive intensity from PMI's IQOS platform, which has achieved $17 billion in smoke-free revenues with 43% of Q1 2026 revenues from these products. BAT's maintained guidance of 3-5% revenue growth and 4-6% adjusted profit growth at the lower end of medium-term ranges suggests management confidence, though execution risks remain elevated.

Thesis Status

The investment thesis faces material headwinds from competitive dynamics revealed in recent developments. PMI's IQOS brand recognition as a top-100 global brand with 35 million users and $10 billion in standalone revenues demonstrates the scale advantage enjoyed by BAT's primary competitor in reduced-risk products. BAT's upgraded mid-teens new-category revenue growth projection, while encouraging, must be contextualized against PMI's 43% smoke-free revenue mix achieved by Q1 2026, suggesting BAT trails in the transition race. The downward revision to cigarette volume expectations (-2.5% vs -2.0%) driven by Asia-Pacific, Middle East, Africa underperformance and heightened U.S. competitive pressure indicates execution challenges in both legacy and growth businesses. The thesis remains viable given BAT's maintained full-year guidance and expanding new-category momentum, but the risk-reward profile has deteriorated as the competitive gap with PMI widens. Investors must weigh BAT's valuation discount against execution uncertainty in capturing share from an increasingly dominant IQOS platform.

Key Drivers

Competitive positioning in reduced-risk products represents the paramount driver, with PMI's IQOS achieving top-100 global brand status and demonstrating superior scale with 35 million users versus BAT's undisclosed new-category user base. The June 2 guidance revision highlighted geographic execution challenges, with slower-than-expected progress in Asia-Pacific, Middle East, and Africa alongside intensified U.S. competition. New-category revenue growth acceleration to mid-teens from low double-digits provides a partial offset, though the magnitude remains below PMI's smoke-free revenue contribution. Regulatory developments continue shaping the landscape, with PMI facing criticism for youth-targeted Marlboro campaigns despite smoke-free commitments, suggesting potential regulatory tightening that could impact all manufacturers. The traditional cigarette business remains cash-generative despite volume declines, enabling continued investment in new categories and shareholder returns, though margin sustainability depends on pricing power retention across markets.

Technical Analysis

BAT shares are trading at £4,566, representing a +2.10% advance since the June 8 report and positioning the stock in the upper portion of the post-correction range. The recovery from the £4,335 June 4 low has retraced approximately 60% of the decline from late May eight-year highs, suggesting constructive momentum. Near-term support has established around £4,450, corresponding to the May 29 levels, while resistance emerges at £4,600-£4,650 based on prior consolidation zones. The YTD gain of +8.35% outpaces the 6-month performance of +6.11%, indicating acceleration in 2026 despite June volatility. Short-term momentum indicators reflect stabilization following the guidance-driven selloff, with the five-day gain of +3.73% and one-month advance of +4.27% demonstrating renewed buying interest. Volume patterns suggest institutional repositioning rather than capitulation, supporting the view that the £4,300-£4,400 zone represents a tactical floor absent further negative catalysts. A sustained move above £4,600 would signal resumption of the primary uptrend, while failure to hold £4,450 could trigger retests of early June lows.

Bull Case

• New-category revenue growth upgraded to mid-teens from low double-digits demonstrates accelerating consumer adoption of vapes and nicotine pouches, validating BAT's smoke-free product portfolio and positioning the company to capture share in the fastest-growing tobacco segments (Morningstar June 2)
• Management maintained full-year guidance of 3-5% revenue growth and 4-6% adjusted profit growth despite cigarette volume headwinds, indicating confidence in pricing power and cost management capabilities to offset structural volume declines (Morningstar June 2)
• Stock trading 13.5% below all-time highs from June 2017 despite improved business mix toward higher-margin reduced-risk products suggests valuation upside as the market re-rates BAT's transition progress (Morningstar May 12)
• Continued revenue and profit momentum in combustible products provides cash generation capacity to fund new-category investments and shareholder returns while managing the business transition (Morningstar June 2)
• Year-to-date gain of +8.35% and 52-week advance of approximately 55% from May 2025 lows demonstrates sustained investor appetite for tobacco exposure amid the sector's transformation toward reduced-risk alternatives (Morningstar May 12)

Bear Case

• PMI's IQOS platform achieved top-100 global brand status with 35 million users and $10 billion in standalone revenues, demonstrating competitive superiority in reduced-risk products that threatens BAT's ability to capture proportionate market share in the fastest-growing segment (Business Wire May 26)
• Cigarette volume decline forecast increased to -2.5% from -2.0% due to slower Asia-Pacific, Middle East, Africa progress and intensified U.S. competition, indicating execution challenges in defending the legacy business that generates majority cash flows (Morningstar June 2)
• PMI achieved 43% of Q1 2026 revenues from smoke-free products with total smoke-free business generating $17 billion in 2025, suggesting BAT trails significantly in the transition race and risks losing market leadership as consumer preferences shift (Business Wire May 26)
• Stock declined -3.2% in early London trading following guidance revision, with subsequent recovery only partially retracing losses, indicating investor skepticism about management's ability to execute the dual mandate of defending combustibles while scaling new categories (Morningstar June 2)
• PMI targeting 66% reduced-risk product revenue by 2030 versus analyst forecasts of 49% demonstrates aggressive competitive positioning that could compress BAT's new-category margins through heightened promotional spending and market share battles (Morningstar May 11)